First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
The country is sixth among the most affected countries by active cases
Previously, the use of the drug was limited to patients requiring hospitalization
UCB plans to submit regulatory applications in Q3 2022
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Subscribe To Our Newsletter & Stay Updated
